SPRO - Spero Therapeutics GAAP EPS of $0.96 beats by $1.06 revenue of $73.5M beats by $54.87M
2024-03-13 16:18:52 ET
More on Spero Therapeutics
- Spero Therapeutics Q4 2023 Earnings Preview
- Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M
- Seeking Alpha’s Quant Rating on Spero Therapeutics
- Historical earnings data for Spero Therapeutics
- Financial information for Spero Therapeutics